These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

552 related items for PubMed ID: 21635992

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
    Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, Reeves KR.
    Arch Intern Med; ; 166(15):1561-8. PubMed ID: 16908788
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.
    Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, Anziano R, Reeves K.
    Arch Intern Med; ; 166(15):1571-7. PubMed ID: 16908789
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial.
    Anthenelli RM, Morris C, Ramey TS, Dubrava SJ, Tsilkos K, Russ C, Yunis C.
    Ann Intern Med; 2013 Sep 17; 159(6):390-400. PubMed ID: 24042367
    [Abstract] [Full Text] [Related]

  • 7. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers.
    Tsai ST, Cho HJ, Cheng HS, Kim CH, Hsueh KC, Billing CB, Williams KE.
    Clin Ther; 2007 Jun 17; 29(6):1027-39. PubMed ID: 17692719
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers.
    Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves KR.
    Clin Ther; 2007 Jun 17; 29(6):1040-56. PubMed ID: 17692720
    [Abstract] [Full Text] [Related]

  • 9. Varenicline: a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation.
    Lam S, Patel PN.
    Cardiol Rev; 2007 Jun 17; 15(3):154-61. PubMed ID: 17438382
    [Abstract] [Full Text] [Related]

  • 10. A perioperative smoking cessation intervention with varenicline: a double-blind, randomized, placebo-controlled trial.
    Wong J, Abrishami A, Yang Y, Zaki A, Friedman Z, Selby P, Chapman KR, Chung F.
    Anesthesiology; 2012 Oct 17; 117(4):755-64. PubMed ID: 22890119
    [Abstract] [Full Text] [Related]

  • 11. Observational study of safety and efficacy of varenicline for smoking cessation among Filipino smokers.
    Park PW, Casiano EM, Escoto L, Claveria AM.
    Curr Med Res Opin; 2011 Oct 17; 27(10):1869-75. PubMed ID: 21838412
    [Abstract] [Full Text] [Related]

  • 12. Tobacco dependence treatment for hospitalized smokers: a randomized, controlled, pilot trial using varenicline.
    Steinberg MB, Randall J, Greenhaus S, Schmelzer AC, Richardson DL, Carson JL.
    Addict Behav; 2011 Dec 17; 36(12):1127-32. PubMed ID: 21835552
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.
    Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR, Varenicline Phase 3 Study Group.
    JAMA; 2006 Jul 05; 296(1):56-63. PubMed ID: 16820547
    [Abstract] [Full Text] [Related]

  • 14. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial.
    Tonstad S, Tønnesen P, Hajek P, Williams KE, Billing CB, Reeves KR, Varenicline Phase 3 Study Group.
    JAMA; 2006 Jul 05; 296(1):64-71. PubMed ID: 16820548
    [Abstract] [Full Text] [Related]

  • 15. Varenicline treatment of concurrent alcohol and nicotine dependence in schizophrenia: a randomized, placebo-controlled pilot trial.
    Meszaros ZS, Abdul-Malak Y, Dimmock JA, Wang D, Ajagbe TO, Batki SL.
    J Clin Psychopharmacol; 2013 Apr 05; 33(2):243-7. PubMed ID: 23422399
    [Abstract] [Full Text] [Related]

  • 16. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial.
    Tashkin DP, Rennard S, Hays JT, Ma W, Lawrence D, Lee TC.
    Chest; 2011 Mar 05; 139(3):591-599. PubMed ID: 20864613
    [Abstract] [Full Text] [Related]

  • 17. Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates.
    Hajek P, McRobbie HJ, Myers KE, Stapleton J, Dhanji AR.
    Arch Intern Med; 2011 Apr 25; 171(8):770-7. PubMed ID: 21518946
    [Abstract] [Full Text] [Related]

  • 18. Varenicline: a first-line treatment option for smoking cessation.
    Garrison GD, Dugan SE.
    Clin Ther; 2009 Mar 25; 31(3):463-91. PubMed ID: 19393839
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial.
    Koegelenberg CF, Noor F, Bateman ED, van Zyl-Smit RN, Bruning A, O'Brien JA, Smith C, Abdool-Gaffar MS, Emanuel S, Esterhuizen TM, Irusen EM.
    JAMA; 2014 Jul 25; 312(2):155-61. PubMed ID: 25005652
    [Abstract] [Full Text] [Related]

  • 20. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
    Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR, Varenicline Phase 3 Study Group.
    JAMA; 2006 Jul 05; 296(1):47-55. PubMed ID: 16820546
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.